A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

Conditions

• T Cell Malignancies

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• ELA026 — DRUG
  Weekly maintenance dosing via subcutaneous injection

Study Details

This is a Phase 1, two-part, multicenter study to evaluate ELA026 in participants ≥18 years old with relapsed/refractory TCM following any line of prior therapy who are eligible for investigational treatments.

Key Dates

Start date

Feb 17, 2026

Status verified

May 2026

Primary completion

Jun 30, 2028

Completion

Dec 31, 2028

Study Design

Enrollment

84 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: Level 0 Arm
  Starting dose level
• Experimental: Level -1 Arm
  Dose level below Starting Dose Level
• Experimental: Level +1 Arm
  Dose level above Starting Dose Level

Primary Outcome Measure

DLTs and treatment emergent adverse events (TEAEs), including serious adverse advents (SAEs) [ Time Frame: DLTs from baseline to DLT window (35 days) and SAEs from baseline through end of safety follow up (approximately 28 weeks for those participants not continuing to optional extension phase) ]

Central Contacts

• Clinical Trials Electra Clinical Trials Information
  Please email
  [email protected]

Locations (4)

Find similar trials in New Haven, CT